Plaque Psoriasis

This study highlights the efficacy and safety of deucravacitinib 6 mg in psoriasis, with results stratified by body mass index and age in a Japanese patient cohort.

Two phase 3 trials met their primary and secondary endpoints in patients with moderate-to-severe plaque psoriasis on envudeucitinib.

This quarterly recap highlights some of the most notable news and developments in the dermatology space from Q4 in 2025.

Investigators conducted a network meta-analysis comparing and ranking the safety and efficacy of dietary supplements as adjunctive therapy for patients with psoriasis.

Investigators explored the measurement properties of the Patient-Reported Outcomes Measurement Information System (PROMIS) among patients with chronic skin disease.

Catch up on news headlines highlighted in the dermatology space by HCPLive in 2025 with this Year in Review.

Catch up on some of the most notable headlines in psoriasis news coverage from 2025 with our Year in Review.

In this analysis, investigators assessed the effects of any weight-loss intervention, behavioural or pharmacological, on the severity of psoriasis as well as quality-of-life outcomes.

Topical steroid withdrawal remains a controversial topic in the dermatology field, given the lack of necessary data.

The highly selective oral TYK2 inhibitor met coprimary endpoints for sPGA 0/1 and PASI 75 at week 16 versus placebo in the phase 3 Latitude studies.

Investigators highlighted patterns of addictive behavior among those with chronic skin diseases in European tertiary dermatology centers.

Vanda Pharmaceuticals submitted a BLA to the FDA for imsidolimab, a novel IgG4 IL-36 receptor antagonist, to treat generalized pustular psoriasis (GPP).

The phase 3 DISCREET study explored the safety and efficacy of apremilast in treating patients with moderate to severe genital psoriasis over 32 weeks.

From diagnosis, investigators sought to explore psoriasis characteristics, patient demographics, patterns of treatment, and disease progression.

Explore the evolving role of AI in dermatology, balancing its benefits with concerns over accuracy, bias, and the human touch in patient care.

This analysis suggests a potential causal association between psoriasis and depression, highlighting the need for mental health screening in patients with psoriasis.

This systematic review and meta-analysis looked at research on the efficacy and safety of topical roflumilast 0.3% in patients with plaque psoriasis.

This review of November 2025 highlights several notable news stories covered in the dermatology space.

In this analysis, investigators explored potential impacts of antibiotic exposure on the persistence of biologic treatments in patients living with psoriasis.

This global analysis highlights the incidence of psoriasis around the world by 2025, noting various distinctions in region, age groups, and sex.

The Psoriasis Study of Health Outcomes (PSoHO) was designed as a 36-month, non-interventional, international cohort study of patients with psoriasis.

The FDA acceptance of Arcutis's supplemental New Drug Application (sNDA) was announced for roflumilast cream 0.3% (Zoryve).

After his sessions on TYK2 Inhibitors for psoriasis and on palmoplantar pustulosis, Vender discussed several key insights in this interview.

Benjamin Locksin speaks in this interview about his session titled ‘Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis.’

Panelists discuss how future oral therapy research should focus on studying younger pediatric populations, implementing early intervention strategies, and investigating whether newer oral agents can reduce the incidence of psoriatic arthritis development.